Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05733442 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation

Study acronym: CHaRRM-CN
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 5, 2026 (before its estimated May 15, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 30, 2025 to May 15, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Jul 31, 2025 to Jul 31, 2026
    • Site details revised at 2 of 2 sites
    v4
  2. Enrollment target: 190 to 136
    • Study description revised
    • Site contacts updated at 1 of 2 sites
    v3
  3. Enrollment target: 160 to 190
    • Primary completion date: Mar 31, 2025 to Jun 30, 2025
    • Site contacts updated at 1 of 2 sites
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this randomized clinical trial is to test the efficacy of a program meant to enhance Counseling for Harm Reduction and Retention in MAT in Cherokee Nation (CHaRRM-CN). The main questions it aims to answer are whether CHaRRM-CN: improves retention of patients in MAT, decreases substance-related harm and illicit opioid use, and increases cultural connectedness. After providing written, informed consent, participants will attend a baseline assessement and will then be randomized to either the CHaRRM-CN or treatment as usual group. For 6 months after randomization, participants will be exposed to CHaRRM-CN or treatment as usual. During that time, participants will also attend the 1-month, 3-month and 6-month follow-ups to track their progress through the programs. After the 6 months of either treatment condition, investigators will compare the groups to see if they differ on retention, substance-use outcomes and Native enculturation.
Trial Details
NCT Number NCT05733442
Lead Sponsor Washington State University
Collaborators: University of Washington, Cherokee Nation Health Services, National Institute on Drug Abuse (NIDA)
Conditions
(from sponsor)		 Opioid Use Disorder
Related terms Harm Reduction, Opioid-Related Disorders
Enrollment 136 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov